bluuebunny/crossref_metadata_2025_split huggingface dataset:
How many people will need palliative care in Scotland by 2040? A mixed-method study of projected palliative care need and recommendations for service delivery
Authors: Finucane Anne M , Bone Anna E , Etkind Simon , Carr David , Meade Richard , Munoz-Arroyo Rosalia , Moine Sébastien , Iyayi-Igbinovia Aghimien , Evans Catherine J , Higginson Irene J , Murray Scott A 
Published: February 2021

ObjectiveTo estimate future palliative care need and complexity of need in Scotland, and to identify priorities for future service delivery.DesignWe estimated the prevalence of palliative care need by analysing the proportion of deaths from defined chronic progressive illnesses. We described linear projections up to 2040 using national death registry data and official mortality forecasts. An expert consultation and subsequent online consensus survey generated recommendations on meeting future palliative care need.SettingScotland, population of 5.4 million.ParticipantsAll decedents in Scotland over 11 years (2007 to 2017). The consultation had 34 participants; 24 completed the consensus survey.Primary and secondary outcomesEstimates of past and future palliative care need in Scotland from 2007 up to 2040. Multimorbidity was operationalised as two or more registered causes of death from different disease groups (cancer, organ failure, dementia, other). Consultation and survey data were analysed descriptively.ResultsWe project that by 2040, the number of people requiring palliative care will increase by at least 14%; and by 20% if we factor in multimorbidity. The number of people dying from multiple diseases associated with different disease groups is projected to increase from 27% of all deaths in 2017 to 43% by 2040. To address increased need and complexity, experts prioritised sustained investment in a national digital platform, roll-out of integrated electronic health and social care records; and approaches that remain person-centred.ConclusionsBy 2040 more people in Scotland are projected to die with palliative care needs, and the complexity of need will increase markedly. Service delivery models must adapt to serve growing demand and complexity associated with dying from multiple diseases from different disease groups. We need sustained investment in secure, accessible, integrated and person-centred health and social care digital systems, to improve care coordination and optimise palliative care for people across care settings.
Mixedwood silviculture in North America: the science and art of managing for complex, multi-species temperate forests
Authors: Kenefic Laura S. , Kabrick John M. , Knapp Benjamin O. , Raymond Patricia , Clark Kenneth L. , D’Amato Anthony W. , Kern Christel C. , Vickers Lance A. , Dey Daniel C. , Rogers Nicole S. 
Published: February 2021

Temperate mixedwoods (hardwood–softwood mixtures) in central and eastern United States and Canada can be classified into two overarching categories: those with shade-tolerant softwoods maintained by light to moderate disturbances and those with shade-intolerant to mid-tolerant softwoods maintained by moderate to severe disturbances. The former includes red spruce (Picea rubens Sarg.), balsam fir (Abies balsamea (L.) Mill.), or eastern hemlock (Tsuga canadensis (L.) Carr.) in mixture with northern hardwood species; the latter includes pine (Pinus) – oak (Quercus) mixtures. Such forests have desirable socio-economic values, wildlife habitat potential, and (or) adaptive capacity, but management is challenging because one or more softwood species in each can be limited by depleted seed sources, narrow regeneration requirements, or poor competitive ability. Appropriate silvicultural systems vary among mixedwood compositions depending on shade tolerance and severity of disturbance associated with the limiting softwoods, site quality, and level of herbivory. Sustainability of mixedwood composition requires that stand structure and composition be managed at each entry to maintain vigorous trees of species with different growth rates and longevities and to encourage development of advance reproduction or seed-producing trees of desired species. Regardless of silvicultural system, maintaining seed sources of limiting softwoods, providing suitable germination substrates, and controlling competition are critical. Here, we describe commonalities among temperate mixedwoods in central and eastern North America and present a framework for managing them.
Quantum effects on radiation friction driven magnetic field generation
Authors: Liseykina Tatyana V. , Macchi Andrea , Popruzhenko Sergey V. 
Published: February 2021

AbstractRadiation losses in the interaction of superintense circularly polarized laser pulses with high-density plasmas can lead to the generation of strong quasistatic magnetic fields via absorption of the photon angular momentum (so-called inverse Faraday effect). To achieve the magnetic field strength of several Giga Gauss, laser intensities $$\simeq 10^{24}\;\mathrm {W/cm}^2$$

≃

10
24

W
/
cm

2

are required which brings the interaction to the border between the classical and the quantum regimes. We improve the classical modeling of the laser interaction with overcritical plasma in the “hole boring” regime by using a modified radiation friction force accounting for quantum recoil and spectral cut-off at high energies. The results of analytical calculations and three-dimensional particle-in-cell simulations show that, in foreseeable scenarios, the quantum effects may lead to a decrease in the conversion rate of laser radiation into high-energy photons by a factor 2–3. The magnetic field amplitude is suppressed accordingly, and the magnetic field energy—by more than one order in magnitude. This quantum suppression is shown to reach a maximum at a certain value of intensity and does not grow with the further increase in intensities. The non-monotonic behavior of the quantum suppression factor results from the joint effect of the longitudinal plasma acceleration and the radiation reaction force. The predicted features could serve as a suitable diagnostic for radiation friction theories.
Traversable wormholes with vanishing sound speed in f(R) gravity
Authors: Capozziello Salvatore , Luongo Orlando , Mauro Lorenza 
Published: February 2021

AbstractWe derive exact traversable wormhole solutions in the framework off(R) gravity with no exotic matter and with stable conditions over the geometric fluid entering the throat. For this purpose, we propose power-lawf(R) models and two possible approaches for the shape functionb(r)/r. The first approach makes use of an inverse power-law function, namely$$b(r)/r\sim r^{-1-\beta }$$b(r)/r∼r-1-β. The second one adopts Padé approximants, used to characterize the shape function in a model-independent way. We single out theP(0, 1) approximant where the fluid perturbations are negligible within the throat, if the sound speed vanishes at$$r=r_0$$r=r0. The former guarantees an overall stability of the geometrical fluid into the wormhole. Finally, we get suitable bounds over the parameters of the model for the above discussed cases. In conclusion, we find that small deviations from general relativity give stable solutions.
Investigations on the electronic structure and optical properties of (Ga,N,Ga-N) doped graphene by first-principle calculations
Authors: Jiang Min , Zhang Wenchao , Zhao Kuo , Guan Feng , Wang Yi 
Published: February 2021

The optical and electronic properties of pure graphene, nitrogen doped graphene, gallium doped graphene and nitrogen and gallium co-doped graphene were researched based on the first-principle method of density functional theory (DFT). Pure graphene has a zero-band structure, and when doped in graphene, its bands are opened. In this study, the bandgap of N-doped graphene was 0.20 eV, Ga-doped graphene was 0.35 eV and N–Ga co-doped graphene was 0.49 eV. They also have different electron density. In the N–Ga co-doped graphene, the N atom gained more electrons (−0.6 1e) than the N-doped graphene (−0.27 e), and the Ga atom lost more electrons (1.80 e) than the Ga-doped graphene (1.75 e). Moreover, the optical properties of pure graphene and doped graphene were analyzed and compared. These properties include complex refractive index, dielectric function and light absorption. From these analysis results, it can be seen that the doping study in graphene has effectively improved the optical and electrical properties of graphene. This study provides an effective theoretical foundation for the future development of graphene-based photoelectric devices.
Periodontal Treatment Improves Serum Levels of Leptin, Adiponectin, and C-Reactive Protein in Thai Patients with Overweight or Obesity
Authors: Wanichkittikul Notkamon , Laohapand Penpan , Mansa-nguan Chayasin , Thanakun Supanee 
Published: February 2021

Periodontitis and overweight or obesity independently change serum levels of leptin, adiponectin, and C-reactive protein (CRP). The aim of this study is to investigate the alterations of serum levels of leptin, adiponectin, and CRP after nonsurgical periodontal treatment (NSPT) in Thai patients with overweight or obesity (Owt/Ob) who did or did not exhibit severe periodontitis (SP) and normal weight (Nwt) patients with or without SP. Two hundred sixty patients were screened; 29 patients were included in this study. The study participants comprised 6 patients with Owt/Ob who exhibited SP, 11 patients with Owt/Ob who did not exhibit SP, 5 Nwt patients with SP, and 7 Nwt patients without SP. Periodontal disease status was evaluated; serum levels of leptin, adiponectin, and CRP were determined by enzyme-linked immunosorbent assay at baseline, as well as at 3 and 6 months after NSPT. At 3 months after NSPT, periodontal status was improved in all groups (

p

< 0.05), except Nwt patients without SP. Serum levels of leptin and CRP were significantly reduced, while serum levels of adiponectin were elevated after NSPT, regardless of bodyweight or waist circumference (

p

< 0.05). Improvement in serum levels of leptin after NSPT was also observed in the Nwt with SP group (

p

= 0.015); these levels did not significantly differ in Nwt patients without SP. NSPT reduces serum levels of leptin and CRP and enhances serum levels of adiponectin in Thai patients with Owt/Ob, irrespective of periodontitis severity. These results suggest a role for periodontal treatment in the systemic inflammatory response of Thai people with Owt/Ob.
Simultaneous Determination of Methamphetamine and Its Isomer N-Isopropylbenzylamine in Forensic Samples by Using a Modified LC-ESI-MS/MS Method
Authors: Luo Yangxu , Du Juan , Xiao Huadi , Zheng Ling , Chen Xuncai , Ma Ande , Luo Qizhi 
Published: February 2021

Accurate identification and quantification of methamphetamine (MA) and its related substances are essential for the investigation and fair trial of drug offenses. In this study, a modified LC-ESI-MS/MS method for the simultaneous determination of MA and its isomer N-isopropylbenzylamine (N-IBA) in forensic samples was developed and validated. Optimum chromatographic separation of the target analytes was achieved on an Agilent Poroshell 120 SB-C18 column (

4.6
×
100

mm, 2.7 μm) at 40°C with isocratic elution at the flow rate of 0.40 mL/min. The mobile phase was acetonitrile and 20 mM ammonium acetate solution containing 0.1% formic acid (80 : 20,

v
/
v

). Positive ESI-MS/MS detection was performed in multiple reaction monitoring (MRM) mode to identify and quantify the target analytes. Method validation showed excellent linearity in the range of 0.51 ng/mL~51 ng/mL for MA and N-IBA. The low limit of detection (LLOD) and low limit of quantification (LLOQ) reached 0.1 ng/mL and 0.3 ng/mL for both analytes. The method showed a satisfactory accuracy with an inter- and intraday-relative error (RE) <20%, and a precision of inter- and intraday relative standard deviation (RSD) less than 15%. The validated method was successfully applied in real forensic samples and resulted in the detection of MA and N-IBA in 8 suspected samples in drug cases that only deemed MA positive using our previous routine screening procedure, which avoided the misidentification of N-IBA as MA.
Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells
Authors: Atienza Josephine M. , Roth Richard B. , Rosette Caridad , Smylie Kevin J. , Kammerer Stefan , Rehbock Joachim , Ekblom Jonas , Denissenko Mikhail F. 
Published: February 2021

Abstract
A genome-wide case-control association study done in our laboratory has identified a single nucleotide polymorphism located in RAD21 as being significantly associated with breast cancer susceptibility. RAD21 is believed to function in sister chromatid alignment as part of the cohesin complex and also in double-strand break (DSB) repair. Following our initial finding, expression studies revealed a 1.25- to 2.5-fold increased expression of this gene in several human breast cancer cell lines as compared with normal breast tissue. To determine whether suppression of RAD21 expression influences cellular proliferation, RNA interference technology was used in breast cancer cell lines MCF-7 and T-47D. Proliferation of cells treated with RAD21-specific small inhibitory RNA (siRNA) was significantly reduced as compared with mock-transfected cells and cells transfected with a control siRNA (Lamin A/C). This inhibition of proliferation correlated with a significant reduction in the expression of RAD21 mRNA and with an increased level of apoptosis. Moreover, MCF-7 cell sensitivity to two DNA-damaging chemotherapeutic agents, etoposide and bleomycin, was increased after inhibition of RAD21 expression with a dose reduction factor 50 (DRF50) of 1.42 and 3.71, respectively. At the highest concentrations of etoposide and bleomycin administered, cells transfected with a single siRNA duplex targeted against RAD21 showed 57% and 60% survival as compared with control cells, respectively. Based on these findings, we conclude that RAD21 is a novel target for developing cancer therapeutics that can potentially enhance the antitumor activity of chemotherapeutic agents acting via induction of DNA damage.
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim
Authors: Nikrad Malti , Johnson Thomas , Puthalalath Hamsa , Coultas Leigh , Adams Jerry , Kraft Andrew S. 
Published: February 2021

Abstract
Previously, we showed that the proteasome inhibitor bortezomib/Velcade (formerly PS-341) synergizes with the protein tumor necrosis factor α–related apoptosis-inducing ligand (TRAIL), a ligand for certain death receptors, to induce apoptosis in cell lines derived from prostate and colon cancers. Because apoptosis is often triggered by BH3-only proteins of the Bcl-2 family, we have explored the hypothesis that bortezomib contributes to the apoptosis by up-regulating their levels. Indeed, bortezomib induced increases of Bik and/or Bim in multiple cell lines but not notably of two other BH3-only proteins (Puma and Bid) nor other family members (Bax, Bak, Bcl-2, and Bcl-xL). The increase in Bik levels seems to reflect inhibition by bortezomib of its proteasome-mediated degradation. Importantly, both Bik and Bim seem central to the proapoptotic function of bortezomib, because mouse embryo fibroblasts in which the genes for both Bik and Bim had been disrupted were refractory to its cytotoxic action. Similarly, the synergy between bortezomib and TRAIL in killing human prostate cancer cells was impaired in cells in which both Bik and Bim were down-regulated by RNA interference. Further evidence that bortezomib acts through the mitochondrial pathway regulated by the Bcl-2 family is that deficiency for APAF-1, which acts downstream of Bcl-2, also blocked its apoptotic effect. These results implicate BH3-only proteins, in particular both Bik and Bim, as important mediators of the antitumor action of bortezomib and establish their role in its enhancement of TRAIL-induced apoptosis.
Abstract IA08: What are some different ways to evaluate immunotherapy combinations?
Authors: Postow Michael 
Published: February 2021

Abstract
This talk will focus on new ways to consider clinical trials testing combinations of immunotherapy agents. Lessons learned from explorations of the combination of PD-1 + CTLA-4 blockade will be shared. Specifically, we will review data related to the concept of treatment free survival as well as highlight recent data using an adaptive/individualized approach to de-escalate combination immunotherapy in patients with advanced melanoma.
Citation Format: Michael Postow. What are some different ways to evaluate immunotherapy combinations? [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2020 Oct 19-20. Philadelphia (PA): AACR; Cancer Immunol Res 2021;9(2 Suppl):Abstract nr IA08.
Abstract PO022: Somatic mutations in tumor infiltrating lymphocytes can affect the expression of immune system genes in the tumor microenvironment
Authors: Anandakrishnan Ramu , Varghese Robin T. , Kinney Nicholas A. , Garner Harold R. 
Published: February 2021

Abstract
Avoiding immune destruction is an emerging hallmark of cancer. It includes tumor cell mutations and epigenetic modifications that allow tumor cells to either evade detection by the immune system, or render the immune response ineffective. However, mutations in tumor infiltrating lymphocytes that inhibit immune response to tumor growth, have not been specifically identified as a hallmark of cancer. We have identified four distinct somatic mutations in tumor infiltrating lymphocytes that affect the expression of immune system genes in tumor samples, suggesting that these lymphocytic mutation may cause a deficient immune response, contributing to cancer progression. These rare mutations occurred frequently in specific cancer types. The T292Nfs*18 mutation in the FETUB gene, R216Gfs*20 in CCDC43, N377D in CLEC4M and V78Gfs*46 in RAB11FIP4 occurred in 13% of breast invasive carcinoma, 41% of colon adenocarcinoma, 12% of ovarian cystadenocarcinoma (OV) and 16% of OV samples respectively, compared to 0.002%, 0.003%, 0.014% and 0.001% in aggregated variant databases. These variants were found in 7-20% of DNA sequences in both tumor and matched normal blood samples, indicating that they originated in tumor infiltrating lymphocytes, rather than in the tumor cells. We argue that these mutations are unlikely to be passenger mutations since each of them occur in only 0-2% of normal tissue samples and in less than 2% of tumor samples from 24-32 of 32 cancer types other than the one noted above for each of the four mutations. The set of differentially expressed genes (FDR&lt;0.05) in samples with each of the four variants, compared to samples without the variant, included 22-445 genes associated with the immune system pathway, suggesting a possible mechanism by which these mutations may affect tumor growth. Given the myriad of diverse mechanisms and genes implicated in cancer, it is not unexpected that mutations in tumor infiltrating lymphocytes could contribute to cancer progression. With further validation, genetic lesions in tumor infiltrating lymphocytes may represent a previously unstudied mechanism affecting tumor growth, and a new class of therapeutic targets. These mutations may also represent potential “somatic” risk markers that may present with age, supplementing traditional germline risk markers.
Citation Format: Ramu Anandakrishnan, Robin T. Varghese, Nicholas A. Kinney, Harold R. Garner. Somatic mutations in tumor infiltrating lymphocytes can affect the expression of immune system genes in the tumor microenvironment [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2020 Oct 19-20. Philadelphia (PA): AACR; Cancer Immunol Res 2021;9(2 Suppl):Abstract nr PO022.
Abstract PO042: Oncostatin M receptor as a therapeutic target of radioimmune therapy in metastatic synovial sarcoma
Authors: Luelling Sarah , Kirkham Matthew , Barrott Jared 
Published: February 2021

Abstract
Synovial sarcoma is a soft tissue malignancy of the muscle that primarily affects adolescents. Due to it low incidence, little advancement has been made in the treatment of this cancer. With an overall survival rate of roughly 40%, the need for new treatments for synovial sarcoma is evident. Oncostatin M Receptor (OSMR) is a type I cytokine receptor and is overexpressed in metastatic synovial sarcoma. OSMR does not have high expression in normal tissues, making it an ideal target for cancer therapy. We hypothesize that by using an anti-OSMR monoclonal antibody conjugated to a radioactive Cu67 isotope, synovial sarcoma can be targeted at both primary and metastatic locations through systemic therapy. Copper67 is a beta radiation emitting isotope that is tissue damaging and able to induce cell death in cancer cells. By conjugating the chelating molecule p-SCN-Bn-NOTA to an anti-OSMR antibody, Cu67 was able to be captured to the antibody. Capture efficiency of Cu67 was measured after TLC separation and found to be 80% efficient. This data suggests that targeting OSMR through radioimmunotherapy (RIT) is a viable treatment and indicates further testing in animal models.
Citation Format: Sarah Luelling, Matthew Kirkham, Jared Barrott. Oncostatin M receptor as a therapeutic target of radioimmune therapy in metastatic synovial sarcoma [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2020 Oct 19-20. Philadelphia (PA): AACR; Cancer Immunol Res 2021;9(2 Suppl):Abstract nr PO042.